PERT

PERT (Prime-Editing-mediated Readthrough of premature Termination codons)

Why in News?
Researchers from the Broad Institute, Harvard University, and the University of Minnesota developed PERT (Prime-Editing-mediated Readthrough of premature Termination codons)—a single genome-editing strategy for many nonsense mutation diseases.
Nonsense Mutation: A single wrong DNA letter adds an early "stop" signal. Protein production quits too soon, leaving the body short on enzymes, transporters, or structural parts.
•    These cause ~25% of genetic diseases—each hitting different proteins at different points.
•    Each needs custom therapy (design, test, approve)—slow and costly.
PERT Solution: Edits a cell's own gene to make a tool that skips early stops, completing full proteins.
How It Works
1. Engineering Spare tRNA
tRNA genes deliver building blocks (amino acids) to the cell's protein assembly line. Cells have many spares, so researchers edit one harmless spare into suppressor tRNA. This modified tRNA ignores disease stops, adds a building block, and lets assembly continue for full proteins.
2. Prime Editing Installation
•    pegRNA: Smart guide finds the exact DNA spot and carries new instructions.
•    PE6c: Main editing enzyme rewrites the gene effectively.
•    PE3: Repair helper locks in changes precisely and safely.
Results: Full proteins restored—17-70% recovery in cells, 1-7% activity in mice. No disruption to normal cell work.
PERT's Effectiveness
Safety: Targets only the intended spot—no DNA damage, no cell disruption. Skips disease stops but respects real protein ends.
Cell Tests (Batten, Tay-Sachs, Niemann-Pick C1):
•    Batten/Tay-Sachs: Enzymes at 17-70% normal levels.
•    Niemann-Pick C1: Full protein produced (normally absent).
Challenges
•    Delivery to target tissues remains difficult.
•    Long-term safety needs more proof.
•    Performance varies across tissues, delaying patient use.